GOLDMAN SACHS GROUP INC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 94 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2021$58,000
-73.6%
17,600
-69.5%
0.00%
Q2 2021$220,000
+144.4%
57,679
+144.4%
0.00%
Q1 2021$90,000
-35.3%
23,604
-23.4%
0.00%
Q4 2020$139,000
-30.5%
30,807
+72.9%
0.00%
Q2 2020$200,000
+55.0%
17,820
-36.1%
0.00%
Q1 2020$129,000
+138.9%
27,878
+101.7%
0.00%
Q2 2018$54,00013,8200.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2020
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders